Care at work - strong stomachs only!
October 2007
Monthly Archive
Wed 31 Oct 2007
Wed 31 Oct 2007
Wed 31 Oct 2007
Sid says "The Coneheads were an alien family, natives of the planet Remulak, who found themselves stranded on Earth. When questioned by Earth neighbors as to their strange behavior, they inevitably replied that they were "from France". Their unearthly appearance, however, was never strongly questioned -- a point from which much of the humor was derived.
Aside from their obvious physical differences, the Coneheads also had a very fast, nasal, monotone speech, and seemed to have much larger appetites than average humans. They would eat massive amounts of food during meals, (which they referred to as "consuming mass quantities"), drink entire six packs of beer at once, and smoke whole packs of cigarettes at a time. Despite their distinctions, they were never suspected of being aliens (even when accidentally referring to their neighbors as "Earthlings") by anyone who encountered them."
Aside from their obvious physical differences, the Coneheads also had a very fast, nasal, monotone speech, and seemed to have much larger appetites than average humans. They would eat massive amounts of food during meals, (which they referred to as "consuming mass quantities"), drink entire six packs of beer at once, and smoke whole packs of cigarettes at a time. Despite their distinctions, they were never suspected of being aliens (even when accidentally referring to their neighbors as "Earthlings") by anyone who encountered them."
Wed 31 Oct 2007
Sepracor has suffered a major decline in third-quarter earnings and is looking to shed some 300 members of its field force.
This move, together with other anticipated cost reduction initiatives across the business, should cut expenses by $90-$100 million in 2008.
Chief executive Adrian Adams said that the GSK deal will add significant long-term value to the [Lunesta] franchise. This, together with the ongoing development of a more focused, targeted and productive commercial organisation, will result in the next phase of growth for Sepracor, he noted, adding that the firm will grow and differentiate our R&D pipeline and aggressively pursue synergistic corporate development and licensing opportunities.
Despite the earnings decline, the news of the job cuts pushed Sepracors shares up 3.7% to $26.73.
Source: PharmaTimes
This move, together with other anticipated cost reduction initiatives across the business, should cut expenses by $90-$100 million in 2008.
Chief executive Adrian Adams said that the GSK deal will add significant long-term value to the [Lunesta] franchise. This, together with the ongoing development of a more focused, targeted and productive commercial organisation, will result in the next phase of growth for Sepracor, he noted, adding that the firm will grow and differentiate our R&D pipeline and aggressively pursue synergistic corporate development and licensing opportunities.
Despite the earnings decline, the news of the job cuts pushed Sepracors shares up 3.7% to $26.73.
Source: PharmaTimes
Wed 31 Oct 2007
